The Motley Fool··Prosper Junior BakinyBeyond Weight Loss: Eli Lilly's Diversified Pipeline Offers More Growth Than Rivals
Eli Lilly's oncology and immunology portfolios rival its blockbuster weight-loss drugs, positioning the company better than Novo Nordisk for long-term growth.
LLYNVOCNTAgene therapyweight loss drugs